NI201600127A - PROTEÍNAS DE FUSIÓN TATk-CDKL5, COMPOSICIONES FORMULACIONES Y USO DE ESTA. - Google Patents

PROTEÍNAS DE FUSIÓN TATk-CDKL5, COMPOSICIONES FORMULACIONES Y USO DE ESTA.

Info

Publication number
NI201600127A
NI201600127A NI201600127A NI201600127A NI201600127A NI 201600127 A NI201600127 A NI 201600127A NI 201600127 A NI201600127 A NI 201600127A NI 201600127 A NI201600127 A NI 201600127A NI 201600127 A NI201600127 A NI 201600127A
Authority
NI
Nicaragua
Prior art keywords
tatk
compositions
formulations
cdkl5 fusion
fusion proteins
Prior art date
Application number
NI201600127A
Other languages
English (en)
Spanish (es)
Inventor
Ciani Elisabetta
Lacconf Franco
Original Assignee
Univ Bologna Alma Mater Studiorum
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Bologna Alma Mater Studiorum filed Critical Univ Bologna Alma Mater Studiorum
Publication of NI201600127A publication Critical patent/NI201600127A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45Transferases (2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4737C-reactive protein
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y207/00Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11022Cyclin-dependent kinase (2.7.11.22)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/20Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/40Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/60Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40Regulators of development
    • C12N2501/405Cell cycle regulated proteins, e.g. cyclins, cyclin-dependant kinases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
NI201600127A 2014-02-28 2016-08-26 PROTEÍNAS DE FUSIÓN TATk-CDKL5, COMPOSICIONES FORMULACIONES Y USO DE ESTA. NI201600127A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461946280P 2014-02-28 2014-02-28

Publications (1)

Publication Number Publication Date
NI201600127A true NI201600127A (es) 2017-03-13

Family

ID=53539745

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201600127A NI201600127A (es) 2014-02-28 2016-08-26 PROTEÍNAS DE FUSIÓN TATk-CDKL5, COMPOSICIONES FORMULACIONES Y USO DE ESTA.

Country Status (33)

Country Link
US (4) US9290746B2 (enExample)
EP (2) EP3608334B1 (enExample)
JP (2) JP6629747B2 (enExample)
KR (1) KR102307276B1 (enExample)
CN (1) CN106255706A (enExample)
AU (2) AU2015221860B2 (enExample)
BR (1) BR112016019868B1 (enExample)
CA (1) CA2940401C (enExample)
CL (1) CL2016002142A1 (enExample)
CR (1) CR20160392A (enExample)
CY (2) CY1122644T1 (enExample)
DK (2) DK3608334T3 (enExample)
DO (1) DOP2016000220A (enExample)
EA (2) EA038000B1 (enExample)
ES (2) ES2885245T3 (enExample)
HR (2) HRP20191511T1 (enExample)
HU (2) HUE045393T2 (enExample)
IL (2) IL247481B (enExample)
LT (2) LT3608334T (enExample)
MX (2) MX2016011167A (enExample)
MY (1) MY181566A (enExample)
NI (1) NI201600127A (enExample)
PE (1) PE20161406A1 (enExample)
PH (1) PH12016501689B1 (enExample)
PL (2) PL3110837T3 (enExample)
PT (2) PT3110837T (enExample)
RS (2) RS59344B1 (enExample)
SG (2) SG10202000537RA (enExample)
SI (2) SI3110837T1 (enExample)
SM (2) SMT201900504T1 (enExample)
SV (1) SV2016005264A (enExample)
WO (1) WO2015128746A2 (enExample)
ZA (2) ZA201606655B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT201900504T1 (it) * 2014-02-28 2019-11-13 Univ Bologna Alma Mater Studiorum Proteine di fusione tatk-cdkl5, composizioni, formulazioni e loro uso
US20210268072A1 (en) * 2016-06-28 2021-09-02 Alma Mater Studiorum - Universitá Di Bologna TATk-CDKL5 Fusion Proteins, Compositions, Formulations, and Use Thereof
US20200299654A1 (en) * 2017-11-30 2020-09-24 Amicus Therapeutics, Inc. Cdkl5 expression variants and cdkl5 fusion proteins
EP4028413A1 (en) 2019-09-10 2022-07-20 Obsidian Therapeutics, Inc. Ca2-il15 fusion proteins for tunable regulation
EP4073231A4 (en) * 2019-10-30 2024-06-05 Amicus Therapeutics, Inc. RECOMBINANT CDKL5 PROTEINS, GENE THERAPY AND METHODS OF PRODUCTION
IT202000025423A1 (it) * 2020-10-27 2022-04-27 Ulisse Biomed S P A Uso di proteine per il trattamento di patologie associate a tossine formanti pori o a proteine virali
IL303239A (en) 2020-12-01 2023-07-01 Univ Pennsylvania Compositions and their uses for the treatment of Engelmann syndrome
WO2025050032A1 (en) * 2023-08-31 2025-03-06 Ultragenyx Pharmaceutical Inc. Methods of producing cdkl5 proteins and uses of the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2632444A1 (en) * 2010-10-25 2013-09-04 Université d'Aix-Marseille TREATMENT OF MeCP2-ASSOCIATED DISORDERS
SMT201900504T1 (it) * 2014-02-28 2019-11-13 Univ Bologna Alma Mater Studiorum Proteine di fusione tatk-cdkl5, composizioni, formulazioni e loro uso

Also Published As

Publication number Publication date
MX2016011167A (es) 2017-04-06
SI3110837T1 (sl) 2019-12-31
EA202190727A3 (ru) 2021-11-30
IL247481A0 (en) 2016-11-30
SG10202000537RA (en) 2020-03-30
HRP20211324T1 (hr) 2021-11-26
JP2020062022A (ja) 2020-04-23
KR20170002372A (ko) 2017-01-06
IL247481B (en) 2020-07-30
JP6896050B2 (ja) 2021-06-30
LT3608334T (lt) 2021-11-25
MY181566A (en) 2020-12-29
EA201691691A1 (ru) 2017-05-31
JP6629747B2 (ja) 2020-01-15
DK3110837T3 (da) 2019-09-16
ZA201906304B (en) 2022-03-30
DK3608334T3 (da) 2021-08-23
EA202190727A2 (ru) 2021-07-30
EA038000B1 (ru) 2021-06-22
BR112016019868A2 (pt) 2017-10-17
EP3608334B1 (en) 2021-05-19
CL2016002142A1 (es) 2017-09-08
RS62244B1 (sr) 2021-09-30
KR102307276B1 (ko) 2021-09-30
WO2015128746A3 (en) 2015-11-26
LT3110837T (lt) 2019-10-10
CN106255706A (zh) 2016-12-21
PH12016501689A1 (en) 2016-10-03
US20180327725A1 (en) 2018-11-15
DOP2016000220A (es) 2016-12-15
NZ723371A (en) 2023-11-24
AU2019219743A1 (en) 2019-09-19
ZA201606655B (en) 2020-05-27
HUE055282T2 (hu) 2021-11-29
EP3110837B1 (en) 2019-06-12
CY1124727T1 (el) 2022-07-22
PE20161406A1 (es) 2017-01-14
RS59344B1 (sr) 2019-10-31
SI3608334T1 (sl) 2021-11-30
AU2019219743B2 (en) 2020-10-29
CR20160392A (es) 2017-06-12
US9944910B2 (en) 2018-04-17
CA2940401C (en) 2022-11-29
AU2015221860A1 (en) 2016-09-08
US20150247134A1 (en) 2015-09-03
CA2940401A1 (en) 2015-09-03
BR112016019868B1 (pt) 2023-11-28
SMT202100478T1 (it) 2021-09-14
PT3608334T (pt) 2021-08-25
US20160194617A1 (en) 2016-07-07
SMT201900504T1 (it) 2019-11-13
AU2015221860B2 (en) 2019-09-12
EP3608334A1 (en) 2020-02-12
US20200199549A1 (en) 2020-06-25
EP3110837A2 (en) 2017-01-04
WO2015128746A2 (en) 2015-09-03
PL3110837T3 (pl) 2020-04-30
SV2016005264A (es) 2017-02-15
PH12016501689B1 (en) 2016-10-03
US9290746B2 (en) 2016-03-22
SG11201606863YA (en) 2016-09-29
PT3110837T (pt) 2019-09-12
HUE045393T2 (hu) 2019-12-30
PL3608334T3 (pl) 2021-11-22
HRP20191511T1 (hr) 2019-11-29
CY1122644T1 (el) 2021-03-12
IL275435B (en) 2021-07-29
MX2020001223A (es) 2022-05-31
ES2745335T3 (es) 2020-02-28
US10584318B2 (en) 2020-03-10
US10907138B2 (en) 2021-02-02
ES2885245T3 (es) 2021-12-13
IL275435A (en) 2020-08-31
JP2017507655A (ja) 2017-03-23
MX392778B (es) 2025-03-24

Similar Documents

Publication Publication Date Title
NI201600127A (es) PROTEÍNAS DE FUSIÓN TATk-CDKL5, COMPOSICIONES FORMULACIONES Y USO DE ESTA.
CL2019000259A1 (es) Anticuerpos, antimiostatina, polipéptidos que contienen regiones fc variantes y métodos de uso.(divisional solicitud 201701584)
AR107078A1 (es) Anticuerpo antimiostatina, polipéptidos que contienen regiones fc variantes así como métodos de uso
CO2019000395A2 (es) Genes de mini–distrofina optimizados y casetes de expresión y su uso
ECSP19026178A (es) Anticuerpos anti-pd-1 y sus usos
CL2017003023A1 (es) Anticuerpos anti-ctla-4 y métodos de uso de los mismos.
ECSP19050049A (es) Anticuerpos anti-ox40 y sus usos
ECSP18094829A (es) Anticuerpos anti-cd40 y sus usos
MX2022006513A (es) Constructos de expresion y metodos para dise?ar geneticamente levadura metilotrofica.
BR112019012342A2 (pt) anticorpos il-11
BR112019007369A2 (pt) anticorpos anti-lag-3 e métodos de uso dos mesmos
BR112019012343A2 (pt) anticorpos il-11ra
PE20210107A1 (es) Anticuerpos anti-cd3 y metodos de uso
MX2022014781A (es) Formulaciones de anticuerpos anti-pdl1.
MX2019004690A (es) Constructos de anticuerpos.
MX2017008817A (es) Composiciones y metodos para la glicosilacion de proteinas.
IL286776A (en) Compositions and methods for preparing t cell compositions and uses thereof
MX2017007585A (es) Anticuerpos anti-c10orf54 y usos de los mismos.
MX2016013963A (es) Metodos mejorados para la elaboracion de terapias celulares adoptivas.
UY34527A (es) ?composiciones, métodos y kits para la preparación de proteínas recombinantes sialiladas?.
MX2016017025A (es) Formulaciones de proteinas.
MX377780B (es) Sobreexpresion de reguladores de la ruta de n-glicosilacion para modular la glicosilacion de proteinas recombinantes.
AR112602A1 (es) ANTICUERPOS ANTI-TrkB
MX2018003445A (es) Expresion de proteinas que contienen fc.
AR110871A1 (es) Proteínas de fusión de factor ix y métodos de fabricación y uso de las mismas